With an average analyst rating of hold, Novartis is clearly not a favorite. But some of the best stock picks are contrarian ...

Detailed price information for Bayer Aktienges ADR (BAYRY) from The Globe and Mail including charting and trades.

In a report released today, Emmanuel Papadakis from Deutsche Bank maintained a Buy rating on Novartis AG, with a price target of CHF115.00. The company’s shares opened today at CHF96.53. Papadakis ...

A memo that purports to summarize a meeting held by members of a biotech trade group suggests deep concern about RFK Jr.’s ...

Novartis is falling farther behind AbbVie, which expanded its JAK inhibitor Rinvoq into giant cell arteritis in April.

Cosentyx missed its main goal in a Phase 3 GCA study, but showed lower steroid use. Novartis plans full review of the trial ...

Novartis (NVS) stock slips as the company's anti-inflammatory agent Cosentyx fails primary goal in a Phase 3 trial for giant ...

Novartis AG’s drug Cosentyx failed in a late-stage study of patients suffering from inflammation in their blood vessels, a ...

Novartis said on Thursday that its Cosentyx drug had failed in a late-stage trial on adults with giant cell arteritis (GCA), ...

Shares have been marching higher, with the stock up 3.7% over the past month. The stock hit a new 52-week high of $121.24 in the previous session. Novartis has gained 24.4% since the start of the year ...

View the latest Novartis AG ADR (NVS) stock price, news, historical charts, analyst ratings and financial information from WSJ.

Novartis AG Sponsored ADR (NVS) is currently at $120.93, up $0.92 or 0.77% --Would be new all-time closing high (Based on available data back to Dec. 24, 1996) --Would be the first record close since ...